sunday, may 29, 2016
12:30-13:30 - Carl von Rokitansky (Brussel) Hall
Meet the Experts - The Medical Puzzle of HoFH
Chairperson: Cesare Sirtori, Italy
- Jeanine Roeters Van Lennep, The Netherlands
- Claudia Stefanutti, Italy
- Marcello Arca, Italy
16:00-17:30 - Nikolai N. Anitschkow (Tirol) Hall
MOVING PCSK9 INHIBITION FORWARD: The Future of Evidence-Based
CV Outcomes in High-Risk Primary and Secondary Prevention Patients
Chairperson: Jean-Claude Tardif, Canada
16:00 – Welcome and Introductions
Jean-Claude Tardif, Canada16:05 – Case-Based Approach to Identifying High-Risk Primary and Secondary
Prevention Patients Michel Farnier, France16:25 – Current Guidelines for High-Risk Patients: The Need for Evidence-Based
Decision Making to Address Remaining Unmet Need G Kees Hovingh, The Netherlands16:45 – Cardiovascular Risk Reduction With PCSK9 Inhibition:
Evidence-Based Long-Term CV Outcomes Jean-Claude Tardif, Canada17:05 - Panel discussion/Q&A
Monday, May 30, 2016
13:00-14:30 - Nikolai N. Anitschkow (Tirol) Hall
PCSK9 inhibitors: a conversation on selecting the right patients
Chairperson: Alberico Catapano, Italy
13:00 - Welcome and introduction
Alberico Catapano, Italy
13:05 - Who is at greatest unmet need?
Michel Farnier, France
13:15 - Clinical perspective
Panel
13:20 - How effective are PCSK9 inhibitors in reducing LDL-C?
Erik Stroes, The Netherlands
13:30 - Clinical perspective
Panel
Which patients find it hardest to achieve recommended LDL-C levels?
13:35 - Familial hypercholesterolaemia
Michel Farnier, France
13:45 - Statin intolerance: GAUSS-3 data
Erik Stroes, The Netherlands
13:55 - Clinical perspective
Panel
14:05 - Will lowering LDL-C with PCSK9 inhibitors reduce CV risk?
Alberico Catapano, Italy
14:15 - Closing Q&A and panel discussion
Panel
14:25 - Chair’s summary and close
Alberico Catapano, Italy
13:00-14:30 - Karl Landsteiner (Innsbruck) Hall
LDL-Cholesterol Update 2016
Chairpersons: Lale Tokgözoglu, Turkey
Pepe Zamorano, Spain
13:00 - Welcome and Introduction – What’s Hot 2016
Lale Tokgözoglu, Turkey
Pepe Zamorano, Spain
13:10 - The Clinical Reality – Attaining Treatment Targets in 2016
Lale Tokgözoglu, Turkey
13:20 - What Do Recent Combination Studies Teach Us? – The Most Recent Insights
Peter Toth, USA
13:45 - Novel Findings on Genetics and Mendelian Randomization
Heribert Schunkert, Germany
14:00 - The Role of Combination Therapy – Defining Treatment Options for the Individual
Patient
Pepe Zamorano, Spain
14:15 - Panel Discussion
Lale Tokgözoglu, Turkey
Pepe Zamorano, Spain
tuesday, May 31, 2016
13:00-14:30 - Karl Landsteiner (Innsbruck) Hall
PCSK9 therapeutics – can we redefine the clinical management of hypercholesterolemia?
Chairperson: John Chapman, France
13:00 - Introduction
John Chapman, France
13:05 - PCSK9 therapeutics – the evidence so far
Eli Roth, USA
13:25 - PCSK9 therapeutics – early insights from the correlation between LDL-C
and cardiovascular events
Kausik Ray, UK
13:45 - PCSK9 therapeutics - what do we have yet to learn?
Ulrich Laufs, Germany
14:05 - Panel Discussion and Q&A
John Chapman, France
Eli Roth, USA
Kausik Ray, UK
Ulrich Laufs, Germany
14:25 - Closing remarks
John Chapman, France
14:00-14:45 - Nikolai N. Anitschkow (Tirol) Hall
Special Lecture: Novel Concept and Clinical Proof to Address Unmet Medical Needs for the Treatment of Rasidual Vascular Risk
Chairpersons: Yuji Matsuzawa, Japan
Jean-Charles Fruchart, France
14:00 - Welcome and Introduction
Yuji Matsuzawa, Japan
Jean-Charles Fruchart, France
14:05 - Novel generation of Peroxisome Proliferator-Activated Receptor alpha (PPARα)
agonists: selective PPARα modulator (SPPARMα)
Jean-Charles Fruchart, France
14:25 - Clinical proof of concept of SPPARMα developed to be more effective and less
harmful
Shun Ishibashi, Japan
14:10-14:55 - Carl von Rokitansky (Brussel) Hall
CETP inhibition – what’s hot in 2016?
Chairperson: Alberico Catapano, Italy
14:10 - Opening by the chair
Alberico Catapano, Italy
14:15 - The pharmacologic basis: Recent insights into kinetics
Gisette Reyes-Soffer, USA
14:25 - Facts, Findings & Expectations
Ulf Landmesser, Germany
14:35 - Is there a need for a new small molecule?
Wouter Jukema, The Netherlands
14:45 - Round Table, Q&A
Alberico Catapano, Italy
14:05-14:50 - Wilhelm Auerswald
(Strassburg) Hall
Introducing Sebelipase alfa, a novel treatment for LAL-D
A case-based meet-the-expert session chaired by Professor Thomas StulnigExperts will present cases on Lysosomal Acid Lipase Deficiency including early treatment results with Sebelipase alfa.
Chair: Thomas Stulnig, AustriaPresenters: Elmar Aigner, Austria
Patrick Gerner, Germany
